International
Albania
Bosnia and Herzegovina
Bulgaria
Croatia
Czech Republic
Estonia
Hungary
Latvia
Lithuania
Kosovo
North Macedonia
Poland
Romania
Serbia
Slovakia
Slovenia
Switzerland (German)
Switzerland (French)
Business Development
Média
Recontrez nous
Carrière
Contact
Nos Produits
Partenaires & Marques
Témoignages
À propos d'Ewopharma
Vision/Mission
Nos valeurs
Notre stratégie
Leadership
Responsabilité sociale
Territoire
Business Development
Média
Recontrez nous
Carrière
Contact
International
Albania
Bosnia and Herzegovina
Bulgaria
Croatia
Czech Republic
Estonia
Hungary
Latvia
Lithuania
Kosovo
North Macedonia
Poland
Romania
Serbia
Slovakia
Slovenia
Switzerland (German)
Switzerland (French)
Média
COMMUNIQUÈS DE PRESSE
1
2
3
4
Suivant
15-04-2026
Sugemalimab Receives I, A Recommendation in ESMO Guideline for Consolidation Therapy in Patients with Stage Ⅲ NSCLC
Lire la suite
26-02-2026
BioGaia AB extends long-standing distribution partnership with Ewopharma
Lire la suite
16-12-2025
Sugemalimab Achieves New Regulatory Milestone: European Commission Approves Stage Ⅲ NSCLC Indication
Lire la suite
26-07-2024
European Commission Approves Sugemalimab
Lire la suite
03-06-2024
AllergyCare AG devient membre du groupe Ewopharma
Lire la suite
1
2
3
4
Suivant
![[Translate to Switzerland (French):]](/fileadmin/user_upload/Ewopharma_CStone_Sugemalimab_01.png "[Translate to Switzerland (French):]")
